A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patients

The primary endpoint of the study is safety and tolerability of MBF-015 administration for 28 days from baseline to end of the follow-up period at Day 43. Number and severity of AEs reported including Clinically Significant Changes in vital signs, physical examination, Laboratory Measurements, ECGs, and Columbia-Suicide Severity Rating Scale (C-SSRS).